Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

NCT01980056 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Vosaroxin

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]